Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amylyx Pharmaceuticals Inc (AMLX)
NASDAQ:AMLX
RESEARCH TOOLSreports
Holding AMLX?
Track your performance easily
Earnings Data
Report Date
Mar 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.56Last Year’s EPS
$0.07Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -37.78%
|Next Earnings Date:Mar 26, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials for the company's pipeline, particularly in Wolfram syndrome and PBH, and maintained a strong financial position. However, challenges include a net loss for the quarter, FDA restrictions on a trial, and discontinued product revenues.Company Guidance
During the third quarter 2024 earnings call, Amylyx Pharmaceuticals provided guidance on several key metrics. The company remains on track to initiate a Phase III trial for avexitide in post-bariatric hypoglycemia (PBH) in Q1 2025, with top-line data expected in 2026. Avexitide has shown a 66% reduction in Level 3 hypoglycemia events and a 53% reduction in Level 2 events in Phase II trials. For AMX0035, positive Phase II data in Wolfram syndrome demonstrated improvement in pancreatic function, and an interim analysis of AMX0035 in PSP is expected mid-2025. The Phase I trial of AMX0114 in ALS is set to begin in Canada, with early cohort data anticipated in 2025. Financially, the company ended Q3 with $234.4 million in cash and investments and projects a cash runway into 2026. Net product revenues were $400,000, with research and development expenses at $21.2 million and SG&A expenses at $17.8 million. The company recorded a net loss of $72.7 million or $1.07 per share for the quarter.Positive Phase II Data for Wolfram Syndrome
Reported positive top-line data from the open-label Phase II HELIOS trial of AMX0035 in 12 participants with Wolfram syndrome, showing improvement in pancreatic function and stabilization across all secondary endpoints.
Strong Financial Position
Ended Q3 with $234.4 million in cash and investments, with a cash runway expected to extend into 2026.
Avexitide Phase III Trial Progress
On track to initiate a pivotal Phase III trial for avexitide in post-bariatric hypoglycemia (PBH) in Q1 2025, with primary efficacy outcome agreed upon by FDA.
Reduction in R&D and SG&A Expenses
Research and development expenses decreased from $30 million to $21.2 million, and SG&A expenses decreased from $48.7 million to $17.8 million compared to the same period in 2023.
Regulatory Progress for ALS Program
Received clearance from Health Canada for the clinical trial application for AMX0114 in ALS and initiated the Phase I LUMINA trial in Canada.
---
AMLX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AMLX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $6.22 | $6.54 | +5.14% |
| Aug 08, 2024 | $1.88 | $1.80 | -4.26% |
| May 09, 2024 | $1.93 | $1.89 | -2.07% |
| Feb 22, 2024 | $15.31 | $18.54 | +21.10% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Amylyx Pharmaceuticals Inc (AMLX) report earnings?
Amylyx Pharmaceuticals Inc (AMLX) is schdueled to report earning on Mar 26, 2025, TBA Not Confirmed.
What is Amylyx Pharmaceuticals Inc (AMLX) earnings time?
Amylyx Pharmaceuticals Inc (AMLX) earnings time is at Mar 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AMLX EPS forecast?
AMLX EPS forecast for the fiscal quarter 2024 (Q4) is -$0.56.
---
